finerenone

FDA Approves Kerendia, First Type 1 CKD Drug

Bayer's Kerendia has won FDA approval as the first new treatment in more than 30 years for adults with chronic kidney disease linked to type 1 diabetes, supported by the FINE-ONE trial and related data. The medicine reduces urinary albumin-to-creatinine ratio and is expected to slow CKD progression, with Bayer positioning Kerendia to complement its existing diabetes and cardiovascular franchises.